/PRNewswire/ Soterix Medical Inc. (SMI), a global leader in non-invasive stimulation and synergistic brain monitoring technologies, announced today that.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Soterix Medical Announces Expanded Clinical Trials for Alzheimer’s disease and Mild Cognitive Impairment
December 24, 2020 GMT
(PRNewsfoto/Soterix Medical)
NEW YORK, Dec. 24, 2020 /PRNewswire/ Soterix Medical Inc. , the global leader in non-invasive stimulation and synergistic brain imaging technologies, is pleased to report expanded clinical trials of its proprietary neuromodulation technologies for Alzheimer’s disease and Mild Cognitive Impairment. Adults over age 65 represent the fastest growing population in the US. Decline in cognitive abilities is a hallmark of advanced age and is associated with loss of independence and dementia risk. Over 50 million adults worldwide are diagnosed with Alzheimer’s disease or other dementia, which puts an enormous burden on individuals, their families and caretakers, and the healthcare system. Soterix Medical technologies are at the forefront